1 |
TRIEBEL F, JITSUKAWA S, BAIXERAS E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4[J]. J Exp Med, 1990, 171(5): 1393-1405.
|
2 |
TRIEBEL F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination[J]. Trends Immunol, 2003, 24(12): 619-622.
|
3 |
SOLINAS C, GARAUD S, DE SILVA P, et al. Immune checkpoint molecules on tumor-infiltrating lymphocytes and their association with tertiary lymphoid structures in human breast cancer[J]. Front Immunol, 2017, 8: 1412.
|
4 |
MATSUZAKI J, GNJATIC S, MHAWECH-FAUCEGLIA P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer[J]. PNAS, 2010, 107(17): 7875-7880.
|
5 |
GOLDBERG MONICA V, DRAKE CHARLES G, LAG-3 in cancer immunotherapy[J]. Curr Top Microbiol, 2011, 344: 269-278.
|
6 |
BAIXERAS E, HUARD B, MIOSSEC C, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class Ⅱ antigens[J].J Exp Med,1992,176(2): 327-337.
|
7 |
WANG J, SANMAMED M F, DATAR I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3[J]. Cell, 2019, 176(1/2): 334-347.e12.
|
8 |
DENG W W, MAO L, YU G T, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2016, 5(11): e1239005.
|
9 |
TASSI E, GRAZIA G, VEGETTI C, et al. Early effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancer[J]. Cancer Res, 2017, 77(4): 851-861.
|
10 |
MENG Q, LIU Z, RANGELOVA E, et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer[J]. J Immunother, 2016, 39(2): 81-89.
|
11 |
HUANG C T, WORKMAN C J, FLIES D, et al. Role of LAG-3 in regulatory T cells[J]. Immunity, 2004, 21(4): 503-513.
|
12 |
JIANG Z, PAN Z, REN X. Progress of PD-1/PD-L1 inhibitors in non-small cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2017, 20(2): 138-142.
|
13 |
LONG L, ZHANG X, CHEN F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy[J]. Genes Cancer, 2018, 9(5/6): 176-189.
|
14 |
HEMON P, JEAN-LOUIS F, RAMGOLAM K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis[J]. J Immunol, 2011, 186(9): 5173-5183.
|
15 |
O’DONNELL J S, TENG M W L, SMYTH M J. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167.
|
16 |
VILLADOLID J, AMIN A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities[J]. Transl Lung Cancer Res, 2015, 4(5): 560-575.
|
17 |
ZHANG J C, CHEN W D, ALVAREZ J B, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity[J].Acta Pharmacol Sin, 2018, 39(11): 1693-1698.
|
18 |
KONG X. Discovery of new immune checkpoints: family grows up[J]. Adv Exp Med Biol, 2020, 1248: 61-82.
|
19 |
陈 锐,王志鑫,樊海宁,等.淋巴细胞活化基因3在肝脏相关疾病中的研究进展[J]. 临床肝胆病杂志,2021,37(4): 977-981.
|
20 |
GODING S R, WILSON K A, XIE Y, et al. Restoring immune function of tumor-specific CD4+T cells during recurrence of melanoma[J]. J Immunol, 2013, 190(9): 4899-4909.
|
21 |
WOO S R, TURNIS M E, GOLDBERG M V, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape[J]. Cancer Res, 2012, 72(4): 917-927.
|
22 |
SHARMA P, ALLISON J P. The future of immune checkpoint therapy[J]. Science, 2015, 348(6230): 56-61.
|
23 |
KIM N, KIM H S. Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells[J]. Front Immunol, 2018, 9: 2041.
|
24 |
GROSS L A, BAIRD G S, HOFFMAN R C, et al. The structure of the chromophore within DsRed, a red fluorescent protein from coral[J].PNAS,2000,97(22): 11990-11995.
|
25 |
王明月, 王 浩, 王冬梅, 等. SIRPα-GFP真核表达载体构建及其在HEK293T细胞中的表达[J]. 吉林大学学报(医学版), 2020, 46(5): 925-929.
|
26 |
THOMAS P, SMART T G. HEK293 cell line: a vehicle for the expression of recombinant proteins [J]. J Pharmacol Tox Met, 2005, 51(3): 187-200.
|
27 |
华 进, 程志彬, 林春霖, 等. 一种高效稳定的磷酸钙转染293T细胞方法的建立及评价[J]. 吉林大学学报(医学版), 2019, 45(5): 1177-1181.
|